Saxo Group Videos

Garnry: Why no-one is talking about the crash in biotech stocks

Biotechnology stocks have fallen significantly since their July peak. But because of the noise about the Volkswagen scandal, Glencore and the China slowdown, it hasn't made the headlines.

Saxo's Peter Garnry says the catalyst has been weaker investment sentiment plus discussions by, among others, Hillary Clinton, on drug price caps. He says investors need to know that there will be an appropriate return on capital, which is under threat from on-going uncertainty.

Peter is still positive on the sector and cites two companies in particular - Gilead Sciences and Biogen - which he says offer attractive long term opportunities.

03:14 minutes
Tags: bio tech, bio tech stocks, bio technology, biogen, biotech, biotech companies, biotech stock, biotech stocks, china, china economy, china economy growth, china equity market, china gdp, china growth, china manufacturing, china outlook, china politics, china slowdown, chinese, chinese economy, equities, equities saxo, equities trading, equity, equity bubble, equity index, equity market, equity markets, equity platform, equity portfolio, equity portfolios, equity research, equity strategy, equity trading, gilead sciences, glencore, glencore mining, saxo, saxo bank, saxo bank saxo tv, saxo bank trading floor, saxo tv, saxo tv saxo bank, saxo tv trading floor, saxo tv tradingfloor, saxo tv tradingfloor.com, saxotv, stock, stock exchange, stock market, stock markets, stock picks, stock price, stock prices, stock trading, stocks, stocks markets, stocks to watch, strategy, trading, tradingfloor, tradingfloor saxo bank, tradingfloor.com, volkswagen, vw, vw scandal